About Microtubule-associated protein RP/EB family member 2
Microtubule-associated protein RP/EB family member 2 (MAPRE2) is a protein
from Homo sapiens identified by UniProt accession
Q15555, 327 residues long.
MolForge cross-references it against 0 known binders and
66 disease associations.
Target properties
| Protein name | Microtubule-associated protein RP/EB family member 2 |
| UniProt accession | Q15555 |
| Gene | MAPRE2 |
| Organism | Homo sapiens |
| Length | 327 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (66)
Diseases linked to this target (Open Targets).
- multiple benign circumferential skin creases on limbs · score 0.59
- neurodegenerative disease · score 0.46
- electrocardiography · score 0.46
- cortical thickness · score 0.41
- cortical surface area measurement · score 0.41
- multiple benign circumferential skin creases on limbs 1 · score 0.37
- creatinine measurement · score 0.32
- Brugada syndrome · score 0.32
- corneal topography · score 0.32
- protein measurement · score 0.32
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15555-F1 | alphafold | PREDICTED | 74.21 | — |
Amino-acid sequence (327 residues)
MPGPTQTLSP NGENNNDIIQ DNNGTIIPFR KHTVRGERSY SWGMAVNVYS TSITQETMSR HDIIAWVNDI VSLNYTKVEQ LCSGAAYCQF MDMLFPGCIS LKKVKFQAKL EHEYIHNFKL LQASFKRMNV DKVIPVEKLV KGRFQDNLDF IQWFKKFYDA NYDGKEYDPV EARQGQDAIP PPDPGEQIFN LPKKSHHANS PTAGAAKSSP AAKPGSTPSR PSSAKRASSS GSASKSDKDL ETQVIQLNEQ VHSLKLALEG VEKERDFYFG KLREIELLCQ EHGQENDDLV QRLMDILYAS EEHEGHTEEP EAEEQAHEQQ PPQQEEY
Explore Microtubule-associated protein RP/EB family member 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets